Hormone Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Intercellular Mediator, Neurotransmitter, Or Fragment Thereof Patents (Class 424/198.1)
  • Patent number: 10350276
    Abstract: The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: July 16, 2019
    Assignee: Novo Nordisk HealthCare AG
    Inventor: Ulla Hedner
  • Patent number: 10335460
    Abstract: Described herein are dose escalation regimens for the administration of complexes comprising interleukin-15 (“IL-15”) covalently or noncovalently bound to IL-15 receptor alpha (“IL-15R?”) to patients in order to enhance IL-15-mediated immune function. In a specific aspect, the dose escalation regimens are useful in the prevention, treatment, and/or management of disorders in which enhancing IL-15-mediated function is beneficial, such as cancer, infectious diseases, immunodeficiencies and lymphopenia. In another specific aspect, the dose escalation regimens are useful for eradicating or reducing HIV in HIV-infected patients.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: July 2, 2019
    Assignees: NOVARTIS AG, The United States of America Department of Health and Human Services
    Inventors: Barbara K. Felber, Sergio Finkielsztein, George N. Pavlakis, John N. Vournakis
  • Patent number: 10307244
    Abstract: A polymer coating/ring is employed to aid in the sealing and connection of modular elements used in body flow lumens for the exclusion and bypass of diseased regions of the flow lumen, such as where aneurysm occurs adjacent to branching blood vessels.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: June 4, 2019
    Assignee: Medtronic Vascular, Inc.
    Inventors: Prema Ganesan, Jonathan Morris, David R. Erickson, Matthew Rust, Curtis Hanson, Jack Chu, Charles Thomas
  • Patent number: 10293030
    Abstract: A pharmaceutical formulation in a lyophilised form, which comprises pharmacologically effective amount of interferon beta-1a as an active ingredient, disaccharides as a bulking agent and a non-ionic surfactant. After reconstitution, the composition can be administered intravenously.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: May 21, 2019
    Assignee: Faron Pharmaceuticals Oy
    Inventors: Markku Jalkanen, Mikael Maksimow, Ilse Piippo
  • Patent number: 10258668
    Abstract: The present invention relates to methods to treat a neurodegenerative disease or disorder, e.g., a motor neuron disease in a subject, whereby the subject is administered a recombinant human Mullerian Inhibiting Substance (MIS) protein as disclosed herein, wherein the recombinant human MIS protein comprises a modified Kex cleavage site for increased cleavage. The recombinant human MIS protein can be produced from a pre-proprotein comprising a non-MIS leader sequence or a functional fragment thereof in place of the MIS leader sequence.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: April 16, 2019
    Assignees: The General Hospital Corporation, Massachusetts Eye and Ear Infirmary, University of Massachusetts
    Inventors: Patricia K. Donahoe, Demetrios Vavvas, David Pepin, Mien Van Hoang, Robert H. Brown, Jr., Guangping Gao
  • Patent number: 10172876
    Abstract: The present invention provides a method of treating a subject afflicted with IgA nephropathy (IgAN) comprising administering to the subject an amount of ginsenoside M1 effective to treat the subject.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: January 8, 2019
    Inventor: Sheau-Long Lee
  • Patent number: 10159705
    Abstract: A method of using fucoidan to enhance stem cell mobilization in a subject, including hematopoietic stem cells (HSCs) and bone marrow stem cells (BMSCs) is provided. In the method, a blended composition of fruits, mushrooms, microorganisms, maternal fluids, and extracts thereof are used to promote trafficking of stem cells, resulting in migration of the stem cells to specific sties of maintenance an and repair within tissues and/or organs. The method also involves the use of fucoidan obtained from particular algae species to support release and circulation of HSCs, as demonstrated by significantly increase circulation of HSCs in the peripheral blood. Increased circulation of HSCs and/or BMSCs and migration towards sites of maintenance and the natural regeneration mechanisms in the body. Further provided is a dosing regimen for the administration of fucoidan and a method of enhancing release and circulation of stem cells.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: December 25, 2018
    Assignee: Stemtech IP Holdings, LLC
    Inventors: Christian Drapeau, Gitte S. Jensen
  • Patent number: 10039808
    Abstract: A method of treating or improving neurological function in a human subject includes identifying a human subject diagnosed with at least one of post-CNS trauma, post-concussion syndrome, a chronic refractive epileptic encephalopathic condition, autism spectrum condition, cerebral palsy; or ischemic long term treatment for remote ischemic or traumatic brain injury; and administering to the human subject a composition comprising a pharmaceutically effective dose of filgrastim.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: August 7, 2018
    Inventor: Michael Chez
  • Patent number: 10030048
    Abstract: Peptides and methods of use thereof, are disclosed for use in treating various disease and disorders, including inflammation, pain, oral mucositis, oral lesions, and cancer. The peptides modulate the activity of the transcription factor NF ?B.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: July 24, 2018
    Inventor: Rajendra Sahai Bhatnagar
  • Patent number: 9976144
    Abstract: Methods for controlling obesity using minimally-invasive procedures including introducing embolic crystal particles that are naturally occurring and mostly non-toxic salts into the arterial capillaries feeding the sections of the stomach where the appetite inducing hormone, ghrelin, is produced to limit the blood flow to the region reducing appetite; introducing a virus vector or antisense oligonucleotide to inhibit the production of ghrelin and reduce the appetite; and introducing a soluble embolic particle with a virus vector or antisense oligonucleotide which will inhibit the flow of blood initially and then dissolve and release the inhibit vector to the region, generating ghrelin to control the appetite.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: May 22, 2018
    Inventor: Mubin I. Syed
  • Patent number: 9879059
    Abstract: A glycopeptide, comprising a polyproline backbone and one or more carbohydrate molecules.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: January 30, 2018
    Assignee: Agency for Science, Technology and Research
    Inventors: Song-Gil Lee, Su Seong Lee, Jaehong Lim, Jian Liang Cheong, Teck Chuan Lim, Shuting Cai
  • Patent number: 9868828
    Abstract: This disclosure provides for a three-dimensional (3D) microenvironment presenting defined physical or mechanical cues that regulate cellular behavior and use of the matrix. The disclosure also provides for devices and methods for screening for optimal combinations of physical and mechanical cues in order to create a microenvironment that can regulate specific cellular behavior such as cell growth, proliferation, migration or differentiation.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: January 16, 2018
    Assignees: AMOLIFESCIENCE CO., LTD., KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP.
    Inventors: Ssang-Goo Cho, Kyuwon Baek, Gwang-Mo Yang, Chan Kim, Jihye Won, In Yong Seo, Dong-Sik Seo, Chulbae Yoo, Hui-Gwan Goo, Seonho Jang, Song Hee Koo, Sang-Eun Park
  • Patent number: 9796787
    Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: October 24, 2017
    Assignee: Vaccibody A/S
    Inventors: Bjarne Bogen, Agnete Brunsvik Fredriksen, Inger Sandlie
  • Patent number: 9758576
    Abstract: Provided herein are antibodies that bind growth factor prodomain complexes, for example, growth factor prodomain complexes that include GDF-8 growth factor and GDF-8 prodomain. Also included are antibodies that bind growth factor prodomain complexes that have been altered by proteolytic processing.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: September 12, 2017
    Assignee: Scholar Rock, Inc.
    Inventors: Thomas Schurpf, Nagesh K. Mahanthappa, Michelle Marie Straub
  • Patent number: 9733261
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in stroke patients and in patients at risk for stroke. In particular, the invention relates to using assays that detect one or more biomarkers as diagnostic and prognostic biomarker assays in such patients.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: August 15, 2017
    Assignee: Astute Medical, Inc.
    Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
  • Patent number: 9655992
    Abstract: Disclosed in certain embodiments is a composition comprising a biological material and transition metal atoms selected from the group consisting of Group IVB, Group VB, Group VIB of the Periodic Chart and a combination thereof, bound to a surface of the biological material.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: May 23, 2017
    Assignee: Orthobond, Inc.
    Inventors: Randell Clevenger, Rong Dong, Jordan Katz
  • Patent number: 9545395
    Abstract: A pharmaceutical composition for enhancing male erectile function comprising an erectile function-enhancing amount of an insulin-like growth factor selected from the group consisting of IGF-1 (Somatmedin-C) and analog LR3 IGF1 in admixture with a pharmaceutically-acceptable diluents or carrier. Such compositions optionally further comprise compounds selected from an androgen, particularly, testosterone and dihydrotestosterone, a vasodilator, PDE5 inhibitor and prostaglandin E1.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: January 17, 2017
    Inventor: Kenneth W. Adams
  • Patent number: 9487754
    Abstract: Provided herein are compositions and methods for forming fibrochondrocytes or fibrochondrocyte-like cells from progenitor cells, such as mesenchymal stem cells. One aspect provides a fibrochondrocyte culture medium including CTGF and TGF?3, optionally encapsulated by microspheres having different release profiles. Another aspect provides a method for forming fibrochondrocytes or fibrochondrocyte-like cells from progenitor cells by culturing with CTGF and TGF?3.
    Type: Grant
    Filed: October 3, 2011
    Date of Patent: November 8, 2016
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Jeremy J. Mao, Chang Hun Lee
  • Patent number: 9468663
    Abstract: There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinsons disease, MS, Alzheimers Disease, Motor Neurone Disease or autism, the composition comprising: (i) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-clostridial agent selected from the above combined with an opioid blocking agent.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: October 18, 2016
    Inventor: Thomas Julius Borody
  • Patent number: 9334314
    Abstract: Peptide compounds derived from human melanotransferrin, and compositions thereof, are described. Uses of these peptide compounds, for example to modulate angiogenesis and/or cell migration, and/or to treat angiogenesis-related disorders (e.g., cancer), are also described.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: May 10, 2016
    Assignee: THERATECHNOLOGIES INC.
    Inventors: Richard Béliveau, Jonathan Michaud-Levesque, Krishna G. Peri, Abdelkrim Habi, Nathalie Bousquet-Gagnon
  • Patent number: 9320778
    Abstract: A product comprising follicle stimulating hormone (FSH) and human chorionic gonadotropin (hCG) for the treatment of infertility.
    Type: Grant
    Filed: September 28, 2011
    Date of Patent: April 26, 2016
    Assignee: Ferring B.V.
    Inventor: Joan-Carles Arce Saez
  • Patent number: 9314505
    Abstract: Viral VEGF and viral anti-inflammatory cytokine compositions, methods of treatment using them, and kits containing them for use in the promotion and/or improvement of wound healing and/or tissue repair, and for anti-scarring, anti-inflammatory, anti-fibrosis and anti-adhesion indications.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: April 19, 2016
    Assignee: OTAGO INNOVATION LIMITED
    Inventors: Lyn Marie Wise, Stephen Bruce Fleming, Andrew Allan Mercer
  • Patent number: 9221873
    Abstract: A short-chain peptide capable of controlling spermatozoa fertilization performance is supplied in an in vitro culture medium of spermatozoa and oocytes to increase the success rates of in vitro fertilization. The short-chain peptide comprises an amino acid sequence H-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-X-NH2 (SEQ ID NO: 1), where X denotes Tyr or Phe, and the sequence ends with an amide. The short-chain peptide is conducive to adjustment of the concentration of free calcium ions inside the cells of the spermatozoa and thus enhancement of the success rates of in vitro fertilization.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: December 29, 2015
    Assignee: NATIONAL TAIWAN UNIVERSITY
    Inventors: Chih-Hsien Chiu, Meng-Chieh Hsu
  • Patent number: 9161968
    Abstract: The present invention provides methods for preventing, attenuating neuronal damage or stimulating neuronal repair prior or following central nervous system injury.
    Type: Grant
    Filed: April 7, 2012
    Date of Patent: October 20, 2015
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The U.S. Government represented by the Department of Veterans Affairs
    Inventors: Anton Wyss-Coray, Jian Luo
  • Patent number: 9084757
    Abstract: This invention relates to an osteogenic device for the de novo induction of bone formation in a mammal. The device contains at least one transforming growth factor-?3 isoform and a retention matrix. The device is introduced by direct injection or surgical implantation into an area where de novo bone formation is desired and, once implanted, the retention matrix acts to retain the TGF-?3 isoform at its place of introduction and forms a scaffold for generated bone, the induction of which is promoted by the TGF-?3 isoform. The device may be used to induce bone growth where bone has been debrided in a surgical procedure and it may also be used to transform neoplastic primary and/or metastatic secondary masses into bone thus facilitating surgical debridement thereof.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: July 21, 2015
    Assignees: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG, RIPAMONTI, UGO BONE RESEARCH LABORATORY, FACULTY OF HEALTH SCIENCES, MEDICAL RESEARCH COUNCIL OF SOUTH AFRICA
    Inventor: Ugo Ripamonti
  • Publication number: 20150147388
    Abstract: The present invention provides materials and methods for modulating an immune response. In one embodiment, the present invention provides an initial artificial lymph-node homing environment, and a simultaneous, or subsequent, artificial spleen environment leading to the resolution of the activated immune responses. In one specific embodiment, the present invention can be used to prevent and/or treat pathogenic infection, cancer, allergenic reactions, and/or unwanted immune or auto-immune responses.
    Type: Application
    Filed: June 25, 2012
    Publication date: May 28, 2015
    Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Clive Henry Wasserfall, Mark A. Atkinson, Benjamin George Keselowsky, Young Mee Yoon
  • Publication number: 20150140007
    Abstract: The present invention provides a composition for treating and/or preventing type I diabetes and an application thereof. The active ingredient of the composition is 1.) or 2.) or 3.), as follows: 1.) a mixture of a type I diabetes protein antigen and an immunosuppressor, 2.) a mixture of a type I diabetes protein antigenic epitope polypeptide and an immunosuppressor, 3.) a mixture of a type I diabetes protein antigen, a type I diabetes protein antigenic epitope polypeptide, and an immunosuppressor; the type I diabetes protein antigen is at least one of insulin, glutamic acid decarboxylase, and islet amyloid polypeptide, and the immunosuppressor is at least one of dexamethasone, cyclosporine A, tacrolimus, mycophenolate mofetil, azathioprine, prednisone, early prednisolone, anti-CD4 monoclonal antibody, and anti-CD3 monoclonal antibody.
    Type: Application
    Filed: April 12, 2013
    Publication date: May 21, 2015
    Inventors: Bin Wang, Guoxing Zheng, Shuang Geng, Yizhong Wang, Qingling Yu
  • Publication number: 20150132340
    Abstract: The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one therapeutic factor. The disclosure also provides methods of reducing an immune suppressor cell population in a mammal, methods of augmenting an immune response in a mammal, and methods of treating a disease in a mammal utilizing the vaccine compositions.
    Type: Application
    Filed: June 13, 2013
    Publication date: May 14, 2015
    Inventors: Kenya Johnson, Eric Jacobson, Frank Bedu-Addo, Mikayel Mkrtichyan, Samir N. Khleif
  • Publication number: 20150110802
    Abstract: Methods are provided for producing a plurality of antibody species in a single animal, comprising delivering a plurality of antigen species to a single animal, where each antigen species is delivered to the animal at an anatomically distinct location. Also provided are methods for generating an immune response in an animal, where each antigen species is delivered to the animal at an anatomically distinct location, under conditions in which the animal produces a plurality of antibody species, where each antibody species specifically binds to a different antigen species among the plurality of antigen species.
    Type: Application
    Filed: February 26, 2013
    Publication date: April 23, 2015
    Applicant: Medlmmune, LLC
    Inventors: Partha S. Chowdhury, Chew-Shun Chang
  • Publication number: 20150110805
    Abstract: Numerous diseases have been linked to the production of effector cells. The present invention relates to the realization that effector cells are cycling in these diseases. In addition, the present invention relates to the determination that regulator cells are cycling in degenerative diseases. Based on these realizations, the present invention provides methods for treating conditions such as autoimmune diseases, degenerative diseases, and graft-versus-host disease. The present invention also relates to methods of determining when therapy should be administered to a patient.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 23, 2015
    Inventors: Martin Leonard Ashdown, Luisa Maria Ashdown
  • Patent number: 8986702
    Abstract: Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to over-express certain proteins.
    Type: Grant
    Filed: May 18, 2009
    Date of Patent: March 24, 2015
    Assignee: Taiga Biotechnologies, Inc.
    Inventors: Yosef Refaeli, Brian Curtis Turner
  • Publication number: 20150079026
    Abstract: The absence of regulatory T cells (Treg) may underlie disorders including but not limited to autoimmunity, dermatitis, periodontitis and even transplant rejection. Enhancing local numbers of Treg through in situ Treg expansion or induction is contemplated herein as a treatment option for these disorders. Current methods for in vivo Treg expansion are not Treg specific and are associated with many adverse side-effects. The data presented herein provides in vitro testing of a Treg-inducing microparticle providing a predictable controlled release for combinations of cytokines and drugs (e.g., IL-2, TGF-?, and/or rapamycin) resulting in targeted Treg migration. These controlled release microparticles are also capable of inducing FoxP3+ Treg in human cells in vitro suggesting that these compositions be developed into an in vivo Treg induction and expansion therapy.
    Type: Application
    Filed: January 22, 2013
    Publication date: March 19, 2015
    Inventors: Steven R. Little, Giorgio Raimondi, Angus W. Thomson, Siddharth Jhunjhunwala
  • Patent number: 8962558
    Abstract: A method for recognizing and evaluating the presence and function of GnRH receptors on tumor cells including those originating in the brain and/or nervous system and/or the meninges and/or reactive neuroglia cells and/or primitive neuroectodermal tumor cells and/or on Kaposi sarcoma is provided. Furthermore, a method for reducing degenerate GnRH-positive tumor cells and/or for decreasing cellular replication of the above GnRH-positive tumor cells comprising administering to a cell or to a subject a replication decreasing amount of a GnRH agonist and/or GnRH antagonist and/or an erythropoietin agonist, and/or a thrombopoietin agonist, and/or a endothelin antagonist and/or a gonadotropin inhibiting hormone agonist is also provided. Furthermore, a diagnostic kit for detecting GnRH receptors on tumor cells according to the present methods is disclosed.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: February 24, 2015
    Inventor: Johannes C. Van Groeninghen
  • Patent number: 8956824
    Abstract: This invention provides a method for identifying allosteric modulators of a SHIP polypeptide, wherein said SHIP polypeptide is contacted with a test compound, and wherein said SHIP polypeptide comprises an allosteric site selected from the group consisting of a SHIP C2 domain and a SHIP PH domain.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: February 17, 2015
    Assignee: British Columbia Cancer Agency Branch
    Inventors: Alice Mui, Christopher Ong, Gerald Krystal, Raymond Andersen
  • Patent number: 8940288
    Abstract: The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example IL-15 (SEQ ID NO: 5, 6), IL-2 (SEQ ID NO: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example IL-15Ra (SEQ ID NO: 7, 8), IL-2Ra (SEQ ID NO: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, SCID, AIDS, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or Lupus. The therapeutic complex of the invention surprisingly demonstrates increased half-life, and efficacy in vivo.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: January 27, 2015
    Assignee: University of Connecticut
    Inventors: Leo Lefrancois, Thomas A. Stoklasek
  • Publication number: 20150023910
    Abstract: Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kD granulysin thereby producing a monocyte-derived dendritic cell. In one example, the method further includes contacting the monocyte or monocyte-derived dendritic cell with a target antigen, such as a tumor antigen or an autoimmune antigen. In another embodiment, the method includes contacting the monocyte with an additional agent that enhances maturation of dendritic cells or induces immunological tolerance. The methods are of use in vivo, in vitro and ex vivo. In another aspect, the disclosure relates to compositions and methods for the treatment of tumors.
    Type: Application
    Filed: July 25, 2014
    Publication date: January 22, 2015
    Inventors: Alan M. Krensky, Carol Clayberger
  • Patent number: 8936792
    Abstract: The present invention provides improved Pseudomonas Exotoxin A (PE) molecules with high cytotoxicity and reduced immunogenicity, compositions containing the improved (PE), and methods of use.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: January 20, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Ira H. Pastan, Richard Beers, Masanori Onda
  • Patent number: 8932603
    Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.
    Type: Grant
    Filed: February 25, 2004
    Date of Patent: January 13, 2015
    Assignee: Vaccibody AS
    Inventors: Bjarne Bogen, Agnete Fredriksen Brunsvik, Inger Sandlie
  • Patent number: 8926983
    Abstract: The present invention comprises novel compositions and methods for eliciting high immune responses, of great specifity yielding conformationally sensitive antibodies. These antibodies recognize specific epitopes on a wide variety of antigens including but not limited to, amyloid protein, prion protein, P170 glycoprotein. The novel compositions of the invention comprise supramolecular antigenic constructs generally comprising a peptide sequence, covalently attached to pegylated lysine resulting in modified and enhanced peptide presentation. The unique modification methodology of the present invention is applicable to a variety of peptides and can ultimately be employed in therapeutic formulations and vaccines for diseases and disorders such as Alzheimer's disease.
    Type: Grant
    Filed: February 22, 2005
    Date of Patent: January 6, 2015
    Assignee: AC Immune SA
    Inventors: Yves Claude Nicolau, Ruth Greferath, David Hickman
  • Patent number: 8900593
    Abstract: Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: December 2, 2014
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Jonathan Day, James Patterson, Joseph Chabenne, Maria DiMarchi, David L. Smiley, Richard D. DiMarchi
  • Patent number: 8883724
    Abstract: Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis. These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and newborn retinopathies, organ transplant rejection, macular degeneration, neovascular glaucoma, hemangioma, and angiofibroma, among others.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: November 11, 2014
    Assignee: Centro de Ingenieria Genética y Biotecnologia
    Inventors: Mónica Bequet Romero, Boris Ernesto Acevedo Castro, Jorge Victor Gavilondo Cowley, Luis Enrique Fernández Molina, Omar Lopez Ocejo, Ricardo de la Caridad Silva Rodriguez, Alexis Musachio Lasa, Ernesto Galban Rodriguez, Dania Marcia Vásquez Blomquist
  • Publication number: 20140294889
    Abstract: The present invention relates to the use of the pituitary adenylate cyclase activating peptide (PACAP) as a molecular adjuvant for vaccines. Among other applications, these vaccines may be used in the protection against infectious agents such as viruses, bacteria and ectoparasites affecting mammals, birds and aquatic organisms. The PACAP, combined with a particular antigen, demonstrates its effectiveness as adjuvant increasing the host immune response against that antigen. This type of response can be observed when the vaccine compositions or combinations that include PACAP are administered orally, by injection, or by immersion baths, in case of aquatic organisms.
    Type: Application
    Filed: August 24, 2012
    Publication date: October 2, 2014
    Applicant: Centro De Ingenieria Genetica y Biotecnologia
    Inventors: Juana Maria Lugo Gonzalez, Yamila Carpio Gonzalez, Mario Pablo Estrada Garcia
  • Patent number: 8846308
    Abstract: Methods of identifying immune response modulators are disclosed. Some methods comprise identifying chemical candidates that modulate oligomerization of FOXP3 and/or fragments thereof comprising the Zinc-LeuZip domains. Some methods comprise identifying chemical candidates that modulate the hetero-oligomerization of FOXP1 with FOXP3 and/or fragments thereof comprising the Zinc-LeuZip domains. Some methods comprise identifying chemical candidates that modulate interaction of IL-2 promoter with FOXP3 and/or fragments thereof comprising the Zinc-LeuZip domains. Method of treating individuals who have or are suspected of having autoimmune disease, inflammatory disease, cell, tissue or organ transplantation, or coronary artery disease, and methods of treating individuals who have or are suspected of having infectious disease, cancer, or who are immunocompromised or undergoing vaccination are disclosed.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: September 30, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Mark I. Greene, Bin Li
  • Patent number: 8840877
    Abstract: Method for preparing an oxidized polysaccharide-protein composition, by (a) oxidizing a polysaccharide with an oxidizing agent to form an oxidized polysaccharide where less than 20% of the oxidized units are comprised of alpha-hydroxy aldehyde units, (b) reacting the oxidized polysaccharide with a protein to form a composition comprising an oxidized polysaccharide-protein conjugate, and (c) maintaining the oxidized polysaccharide-protein conjugate composition by placing it in an environment where the temperature is less than 8° C. The oxidized polysaccharide and the protein are conjugated via one or more imine bonds, the oxidized polysaccharide-protein composition is soluble in aqueous solvent, and the composition is capable of releasing the protein.
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: September 23, 2014
    Assignee: Therapure Biopharma Inc.
    Inventors: Gord Adamson, David Bell, Steven Brookes
  • Patent number: 8828723
    Abstract: Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: September 9, 2014
    Assignee: Taiga Biotechnologies, Inc.
    Inventors: Yosef Refaeli, Brian Curtis Turner
  • Publication number: 20140248211
    Abstract: The invention provides a method for treating cancer using a coadministration strategy that combines local codelivery of a therapeutic agent and an intracellular penetration enhancing agent, and optionally in further combination with local administration of an immunotherapeutic agent, such as a cancer vaccine or NKT agonist. The invention also provides a method for treating cancer using an intracellular penetration enhancing agent. The methods of the invention aim to substantially kill and/or destroy the target tumor cells, as well as those cancerous cells that have metastasized to other parts of the body.
    Type: Application
    Filed: May 16, 2014
    Publication date: September 4, 2014
    Applicant: INTENSITY THERAPEUTICS, INC.
    Inventor: Lewis H. Bender
  • Publication number: 20140234423
    Abstract: Biomaterial systems, e.g., gel scaffolds, are used in vivo to recruit immune cells and promote their activation towards a non-inflammatory phenotype, thereby leading suppression of inflammation. The compositions and methods are useful to reduce the severity of autoimmunity, chronic inflammation, allergy, and periodontal disease.
    Type: Application
    Filed: February 20, 2014
    Publication date: August 21, 2014
    Applicants: FORSYTH DENTAL INFIRMARY FOR CHILDREN, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Roger Warren Sands, Eduardo Alexandre Barros e Silva, Toshihisa Kawai, David J. Mooney
  • Patent number: 8795672
    Abstract: Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a liver-expressed chemokine (LEC). In one embodiment, the cancer targeting molecule is an antibody that targets cancer cells or tumors in vivo. The cancer targeting molecule is associated non-covalently or covalently with LEC. The cancer therapeutic agents of the invention are useful for the treatment of cancer in an individual by reducing the size of a tumor or inhibiting the growth of cancer cells in an individual and/or by inhibiting the development of metastasis. The effectiveness of the therapy using the LEC cancer therapeutic agents can be increased by reducing the activity of immunoregulatory T cells and/or by adoptively transferring immune T cells.
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: August 5, 2014
    Assignee: University of Southern California
    Inventors: Alan L. Epstein, Jiali Li, Peisheng Hu
  • Publication number: 20140178334
    Abstract: This invention relates to compositions and methods for immunotherapy of cancer. Specifically, a method of cancer immunotherapy is described which results in the systemic liquidation of both solid and metastatic tumors whereever they reside in the body. The compositions include activated allogeneic Th1 cells that when administered appropriately lead to liquidation of tumors. The method includes administering priming doses of the therapeutic composition, ablation of a selected tumor lesion along with intratumoral injection of the composition and then infusion of the therapeutic composition. These steps enable the systemic liquidation of tumors secondary to immune cell infiltration and leads to immune-mediated tumor eradication.
    Type: Application
    Filed: February 28, 2014
    Publication date: June 26, 2014
    Applicant: Immunovative Therapies, Ltd.
    Inventor: Michael Har-Noy
  • Publication number: 20140178400
    Abstract: The present invention relates to compositions and methods for modulation of TH17 responses. The invention provides compositions for the induction of TH17 responses containing a TLR agonist and an apoptotic cell-associated agent or containing a microbe-infected apoptotic cell. The compositions of the present invention may also contain dendritic cells capable of inducing TH17 responses. In other embodiments, the invention provides compositions for the inhibition of TH17 responses containing one or more blocking agents. Methods and compositions for the modulation of TH17 responses and for the treatment of TH17-associated diseases and for cancer are also provided.
    Type: Application
    Filed: December 13, 2013
    Publication date: June 26, 2014
    Inventors: Julie Magarian Blander, Miriam Torchinsky